dc.creator | Liaskos C., Marou E., Simopoulou T., Barmakoudi M., Efthymiou G., Scheper T., Meyer W., Bogdanos D.P., Sakkas L.I. | en |
dc.date.accessioned | 2023-01-31T08:55:06Z | |
dc.date.available | 2023-01-31T08:55:06Z | |
dc.date.issued | 2017 | |
dc.identifier | 10.1080/08916934.2017.1357699 | |
dc.identifier.issn | 08916934 | |
dc.identifier.uri | http://hdl.handle.net/11615/75906 | |
dc.description.abstract | Background: Autoantibodies (autoAbs) help in diagnosis and predicting clinical phenotypes in systemic sclerosis (SSc). Aim of the study: To determine the clinical utility of 13 SSc-related autoAbs in SSc patients. Material and methods: A total of 131 consecutive patients with SSc (111 female, mean age 58.1 ± 14 years; 49 with diffused cutaneous SSc [dcSSc] and 82 with limited cutaneous SSc [lcSSc]) were analysed by a multiplex line immunoassay (Euroimmun) for autoantibodies (autoAbs) against 13 SSc-related antigens. A total of 22 patients with primary Raynaud phenomenon (RP), and 22 healthy controls were also analysed. Results: ANA by indirect immunofluorescence was present in 128 (97.7%) patients with SSc. Excluding anti-Ro52, 113 (89.3%) SSc patients were positive for at least one autoAb: anti-Topoisomerase I (anti-Topo) I abs in 54 (41.2%), anti-centromere proteins (anti-CENP) in 37 (28.2%, all reactive with centromere protein-A (CENPA) and centromere protein B (CENPB)), anti-RNA polymerase III(RP11) in 19 (14.5%), anti-RNA polymerase III(RP155) in 13 (9.9%), anti-fibrillarin in 4 (3.1%), anti-Ku in 6 (4.6%), anti-nucleolus-organizing region (anti-NOR90) in 8 (6.1%), anti-PM-Scl100 in 2 (1.5%), and anti-PM-Scl75 in 4 (3.1%). There was no immunoreactivity for Th/To or platelet-derived growth factor receptor (PDGFR). Overall, 102 (77.9%) SSc patients had autoAbs against Topo I, CENPA or CENPB, RP11 or RP155. Anti-Topo I abs were strongly associated with dcSSc, interstitial lung disease (ILD) (p <.001), pulmonary hypertension (PH) (p =.019) and ILD-PH (p =.003). Anti-CENPB abs were associated with lcSSc, and negatively associated with ILD. Anti-RP11 and anti-NOR90 abs were associated with male gender, and anti-NOR90 associated with ILD. Conclusions: Anti-Topo I, anti-CENP, and anti-RNA pol III are the most prevalent autoAbs in SSc. Anti-Topo I and anti-NOR90 abs are associated with ILD and/or PAH. © 2017 Informa UK Limited, trading as Taylor & Francis Group. | en |
dc.language.iso | en | en |
dc.source | Autoimmunity | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85026367512&doi=10.1080%2f08916934.2017.1357699&partnerID=40&md5=9d518e0f7528882ae11e3bd457863c51 | |
dc.subject | autoantibody | en |
dc.subject | centromere antibody | en |
dc.subject | centromere protein A | en |
dc.subject | centromere protein B | en |
dc.subject | DNA directed RNA polymerase III | en |
dc.subject | DNA topoisomerase | en |
dc.subject | fibrillarin | en |
dc.subject | Ku antigen | en |
dc.subject | nucleolus organizing region 90 antibody | en |
dc.subject | platelet derived growth factor receptor | en |
dc.subject | scl 100 antibody | en |
dc.subject | scl 75 antibody | en |
dc.subject | unclassified drug | en |
dc.subject | autoantibody | en |
dc.subject | autoantigen | en |
dc.subject | epitope | en |
dc.subject | immunoglobulin G | en |
dc.subject | adult | en |
dc.subject | antibody titer | en |
dc.subject | Article | en |
dc.subject | controlled study | en |
dc.subject | female | en |
dc.subject | gender | en |
dc.subject | human | en |
dc.subject | immunofluorescence | en |
dc.subject | immunoreactivity | en |
dc.subject | interstitial lung disease | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | middle aged | en |
dc.subject | pulmonary hypertension | en |
dc.subject | Raynaud phenomenon | en |
dc.subject | systemic sclerosis | en |
dc.subject | aged | en |
dc.subject | autoimmunity | en |
dc.subject | immunoassay | en |
dc.subject | immunology | en |
dc.subject | prevalence | en |
dc.subject | systemic sclerosis | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Autoantibodies | en |
dc.subject | Autoantigens | en |
dc.subject | Autoimmunity | en |
dc.subject | Epitopes | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Immunoassay | en |
dc.subject | Immunoglobulin G | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Prevalence | en |
dc.subject | Scleroderma, Systemic | en |
dc.subject | Taylor and Francis Ltd | en |
dc.title | Disease-related autoantibody profile in patients with systemic sclerosis | en |
dc.type | journalArticle | en |